ABL Bio
OverviewSuggest Edit
ABL Bio is a biotech research company focusing on the development of therapeutic drugs for immuno-oncology and neurodegenerative disease. It offers a range of bispecific antibody platforms.
| Type | Private | |
| Founded | 2016 | |
| Website | ablbio.com |
Recent NewsAll News
- Insights on the Antibody Drug Conjugates Global Market to 2030 - Featuring 6 Dimensions Capital, AbbVie and ABL Bio Among Others
- ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific Antibody
- ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody
- I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors
Latest Updates
| Employees (est.) (Jan 2022) | 33 | (+4%) |
| Cybersecurity rating | C | More |
ABL Bio Financials and Metrics
Summary Metrics
Founding Date | 2016 |
ABL Bio total Funding | $90.8 m |
ABL Bio latest funding size | $65 m |
Time since last funding | 4 years ago |
ABL Bio investors | Korea Investment Partners, DSC Investment, DS Asset Management, QUAD Investment Management, Alpen Route Asset Management, Hana Financial Investment, HantuPa |
ABL Bio's latest funding round in June 2018 was reported to be $65 m. In total, ABL Bio has raised $90.8 m
ABL Bio Cybersecurity Score
ABL Bio Online and Social Media Presence
ABL Bio's Trends
ABL Bio News and Updates
October 08, 2021
Insights on the Antibody Drug Conjugates Global Market to 2030 - Featuring 6 Dimensions Capital, AbbVie and ABL Bio Among Others
Dublin, Oct. 08, 2021 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market by Indication, Linker, Payload, Target Antigens and Geography: Industry Trends and Global Forecasts, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
August 04, 2021
ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific Antibody
South Korea's MFDS clears IND application for a Phase 1 study evaluating the safety and preliminary efficacy of ABL501 as a monotherapy for solid tumor treatment ABL's third IND this year for bispecific antibody therapeutics SEONGNAM, South Korea, Aug. 4, 2021 /PRNewswire/ -- ABL Bio, Inc....
July 09, 2021
ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody
ABL503/TJ-L14B demonstrates stronger anti-tumor efficacy than anti-PD-L1 or anti-4-1BB monotherapy as well as a good safety profile ABL503 currently in Phase 1 trial to evaluate the safety, tolerability, MTD PK and PD in patients with advanced or metastatic solid tumors SEONGNAM, South...
March 30, 2021
I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors
SHANGHAI, China and GAITHERSBURG, Md., March 30, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the development of novel biologics, and ABL Bio, Inc. (Kosdaq:298380, hereafter “ABL”), a South Korean biotech specializing in bis…
ABL Bio Frequently Asked Questions
When was ABL Bio founded?
ABL Bio was founded in 2016.
How many employees does ABL Bio have?
ABL Bio has 33 employees.
Who are ABL Bio competitors?
Competitors of ABL Bio include Courier Therapeutics, ImmVira and Precision Medicines.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies